KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Revenue: 2011-2024

Historic Revenue for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $332.3 million.

  • Esperion Therapeutics' Revenue rose 69.10% to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $303.8 million, marking a year-over-year increase of 2.83%. This contributed to the annual value of $332.3 million for FY2024, which is 185.66% up from last year.
  • As of FY2024, Esperion Therapeutics' Revenue stood at $332.3 million, which was up 185.66% from $116.3 million recorded in FY2023.
  • Esperion Therapeutics' Revenue's 5-year high stood at $332.3 million during FY2024, with a 5-year trough of $75.5 million in FY2022.
  • Moreover, its 3-year median value for Revenue was $116.3 million (2023), whereas its average is $174.7 million.
  • Its Revenue has fluctuated over the past 5 years, first slumped by 65.52% in 2021, then skyrocketed by 185.66% in 2024.
  • Yearly analysis of 5 years shows Esperion Therapeutics' Revenue stood at $227.5 million in 2020, then crashed by 65.52% to $78.4 million in 2021, then decreased by 3.79% to $75.5 million in 2022, then spiked by 54.14% to $116.3 million in 2023, then surged by 185.66% to $332.3 million in 2024.